463 related articles for article (PubMed ID: 34090928)
1. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
4. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
5. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
[TBL] [Abstract][Full Text] [Related]
7. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
10. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
11. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review.
Lee J; Vali Y; Boursier J; Spijker R; Anstee QM; Bossuyt PM; Zafarmand MH
Liver Int; 2021 Feb; 41(2):261-270. PubMed ID: 32946642
[TBL] [Abstract][Full Text] [Related]
12. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
13. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value.
Higuera-de-la-Tijera F; Córdova-Gallardo J; Buganza-Torio E; Barranco-Fragoso B; Torre A; Parraguirre-Martínez S; Rojano-Rodríguez ME; Quintero-Bustos G; Castro-Narro G; Moctezuma-Velazquez C
Dig Dis Sci; 2021 Dec; 66(12):4501-4507. PubMed ID: 33428035
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
[TBL] [Abstract][Full Text] [Related]
15. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
[TBL] [Abstract][Full Text] [Related]
16. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.
Hagström H; Talbäck M; Andreasson A; Walldius G; Hammar N
Gastroenterology; 2020 Jan; 158(1):200-214. PubMed ID: 31563624
[TBL] [Abstract][Full Text] [Related]
17. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
[TBL] [Abstract][Full Text] [Related]
18. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
[TBL] [Abstract][Full Text] [Related]
19. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
[TBL] [Abstract][Full Text] [Related]
20. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
